Follicular lymphoma (FL) is a heterogeneous disease. For many it is experienced as a
chronic, relapsing, indolent condition with long overall survival (OS). Most people affected …

Background Because follicular lymphoma (FL) patients have heterogeneous outcomes, the
FL international prognostic index (FLIPI) was developed to risk-stratify patients and to predict …

Background Less than 20% of patients with follicular lymphoma (FL) present with Ann Arbor
Stage I or II disease at diagnosis. Numerous therapeutic options exist, however radiation …

Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …

Follicular lymphoma (FL) can vary markedly in its initial presentation, and no single standard
approach for its initial management has been adopted. Available options for the initial …

Background Follicular lymphoma (FL) is a common form of non-Hodgkin lymphoma with a
wide spectrum of presentation. While grade 1/2 FL is considered low grade and grade 3B FL …

The overall outcome of patients with advanced-stage follicular lymphoma (FL) has improved
significantly. However, some patients still develop multiple relapsed/refractory FL (RRFL). To …

Background: Previous trials from the Swiss Group for Clinical Cancer Research (SAKK) and
the Nordic Lymphoma Group (NLG) showed that therapy with single-agent rituximab can …

Abstract Introduction The PRIMA (Primary Rituximab and Maintenance) study established 2
years of maintenance rituximab (MR) as a standard of care for follicular lymphoma (FL) …

Whilst recent advances in the treatment of follicular lymphoma (FL) have improved the
outlook for many patients, relapses still occur and the search continues for strategies to …